 Tonix Pharmaceuticals Holding Corp NASDAQ: TNXP says that as expected, TNX-102 SL cyclobenzaprine HCl sublingual tablets did not significantly reduce fibromyalgia daily pain at Week 14 compared to placebo in the Phase 3 RALLY study. Tonix reported interim analysis. 